General Interest

The Pioneer Platform features one of the largest functional antibody libraries available, utilizing SpyLock technology for rapid prototyping and screening of hundreds of bispecific antibodies, and TrailBlazer technology for efficient antibody format conversion. Together, these services provide a comprehensive and streamlined solution for researchers seeking to develop innovative biotherapeutic therapies.

Most scientists, no matter where they are at in their career, remember the moments of wonder as they navigated lab work for the first time. Whether it’s a band on a gel, a colony on a plate, or a piece of data, those first tangible results come with a feeling of having accomplished something incredible. More than ten years later, we caught up with two scientists who immortalized that feeling in the form of matching protein ladder tattoos, and discussed how their time as undergraduate researchers led them where they are today.

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.

Feeling stressed? Take a break with this qPCR-themed word search.

We asked core facilities staff and research scientists from the U.S. and Europe for their top tips for securing funding for large instrumentation, such as a cell analyzer or cell sorter. Here are the key questions you should consider while preparing your grant application to increase your chances of a successful outcome.

No patient who has survived cancer wants to hear that they’ve relapsed. But hearing it sooner rather than later can dramatically increase the chances of finding a successful, potentially life-saving treatment. Using next-generation sequencing and Droplet Digital PCR, researchers at the University of Uppsala aim to detect relapse by monitoring patient-specific biomarkers. Read about their ongoing clinical study.

Research into human diseases has led to the development of novel monoclonal antibody drugs. These monoclonal antibody therapies have been successful because of their specificity and selectivity. However, ongoing development and successfully launching a new mAb drug require robust and reliable methods to screen for drug targets, demonstrate drug safety and efficacy, and scale up manufacturing to meet the stringent regulatory guidelines required for approval.

Join us for an in-depth dive into western blotting. Whether you are new to western blotting or an experienced user looking for tips, this five-part webinar series has something for you. Slides and downloadable resources will be available for each webinar. Complete all five classes to receive a certificate of completion and a colorful Western Blotting University poster.

The ability to characterize the target of cell-mediated immune response is crucial during vaccine development. In studying the characterization of SARS-CoV-2 infection pathogenesis in humans, a research team identified neutralizing antibodies that provided context for vaccine antigen design. Discover how the ZE5 Cell Analyzer was used to detect activation-induced markers, measure intracellular cytokines, and identify spike protein–specific antibodies in a rapid, high-throughput manner.

Bio-Rad is proud to introduce our new RT-PCR testing kits for COVID-19. These all-in-one kits are designed for sensitive, specific detection of SARS-CoV-2 alone, or simultaneous detection of SARS-CoV-2, influenza A, and influenza B. Read on to learn about each kit’s features.